141 related articles for article (PubMed ID: 12616851)
1. Letter to the ISPE commentary editor.
Rawson NS
Pharmacoepidemiol Drug Saf; 2003; 12(1):71-2. PubMed ID: 12616851
[No Abstract] [Full Text] [Related]
2. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
3. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
4. Postmarketing modifications in the safety labeling of the new antiepileptics.
Buck ML; Gurka MJ; Goodkin HP
Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
[No Abstract] [Full Text] [Related]
5. Re-examining our approach to the approval and use of new drugs.
Lee SK
CMAJ; 2006 Jun; 174(13):1855. PubMed ID: 16785460
[No Abstract] [Full Text] [Related]
6. The quantification of drug risks in practice.
Lee D; Bergman U
WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
[No Abstract] [Full Text] [Related]
7. Consumer groups look to improve adverse event reporting systems.
Vastag B
J Natl Cancer Inst; 2005 Dec; 97(24):1804-5. PubMed ID: 16368939
[No Abstract] [Full Text] [Related]
8. European commission consultation on pharmacovigilance.
Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
[No Abstract] [Full Text] [Related]
9. The drug safety system conundrum.
Tiedt TN
Food Drug Law J; 2007; 62(3):547-558. PubMed ID: 17915396
[No Abstract] [Full Text] [Related]
10. Global harmonization is not all that global: divergent approaches in drug safety.
Castle GH; Kelly B
Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
[No Abstract] [Full Text] [Related]
11. Roadmap for revitalization?
Nat Biotechnol; 2007 Oct; 25(10):1061. PubMed ID: 17921973
[No Abstract] [Full Text] [Related]
12. Drug approval system questioned in US and Canada.
Eggertson L
CMAJ; 2005 Feb; 172(3):317-8. PubMed ID: 15684107
[No Abstract] [Full Text] [Related]
13. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Jacobson JD; Feigal D
Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
[No Abstract] [Full Text] [Related]
14. US Senate passes FDA Revitalization Act.
Guthrie P
CMAJ; 2007 Jul; 177(1):23. PubMed ID: 17606930
[No Abstract] [Full Text] [Related]
15. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
16. Lessons from Eprex for biogeneric firms.
Louët S
Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
[No Abstract] [Full Text] [Related]
17. Industry reneges on postmarketing trial commitments.
Bouchie A
Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
[No Abstract] [Full Text] [Related]
18. [Immunization: adverse event reporting system].
Weil-Olivier C; Jacquet A
Arch Pediatr; 2006 Jun; 13(6):646-8. PubMed ID: 16697590
[No Abstract] [Full Text] [Related]
19. Mandatory pharmacovigilance.
Maksymowych WP
CMAJ; 2003 Mar; 168(6):672; discussion 672-3. PubMed ID: 12642413
[No Abstract] [Full Text] [Related]
20. FDA guidance document on monitoring delayed adverse events a good first start.
Williams DA
Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
[No Abstract] [Full Text] [Related]
[Next] [New Search]
